NASDAQ:RCM - R1 RCM Stock Price, Forecast & News

R1 RCM trades on the NASDAQ under the ticker symbol "RCM."

R1 RCM Inc (NASDAQ:RCM) issued its quarterly earnings data on Tuesday, November, 5th. The healthcare provider reported $0.01 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.09 by $0.08. The healthcare provider had revenue of $301.20 million for the quarter, compared to analysts' expectations of $302.85 million. R1 RCM had a negative net margin of 0.13% and a positive return on equity of 100.31%. The company's revenue for the quarter was up 20.3% on a year-over-year basis. During the same quarter last year, the company earned ($0.17) earnings per share. View R1 RCM's Earnings History.

R1 RCM is scheduled to release their next quarterly earnings announcement on Friday, February 28th 2020. View Earnings Estimates for R1 RCM.

4 Wall Street analysts have issued 1-year price targets for R1 RCM's shares. Their forecasts range from $14.00 to $17.00. On average, they expect R1 RCM's stock price to reach $15.25 in the next twelve months. This suggests a possible upside of 13.2% from the stock's current price. View Analyst Price Targets for R1 RCM.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for R1 RCM in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for R1 RCM.

Media stories about RCM stock have been trending positive this week, according to InfoTrie. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. R1 RCM earned a media sentiment score of 2.2 on InfoTrie's scale. They also assigned news headlines about the healthcare provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for R1 RCM.

R1 RCM saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 7,780,000 shares, an increase of 17.3% from the December 15th total of 6,630,000 shares. Based on an average trading volume of 1,130,000 shares, the short-interest ratio is presently 6.9 days. Currently, 8.0% of the company's stock are sold short. View R1 RCM's Current Options Chain.

Some companies that are related to R1 RCM include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Davita (DVA), Chemed (CHE), Amedisys (AMED), LHC Group (LHCG), AMN Healthcare Services (AMN), BioScrip (BIOS), MEDNAX (MD), CorVel (CRVL), Tivity Health (TVTY), The Providence Service (PRSC), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG).

Based on aggregate information from My MarketBeat watchlists, some companies that other R1 RCM investors own include Alibaba Group (BABA), NVIDIA (NVDA), Baozun (BZUN), Marvell Technology Group (MRVL), JD.Com (JD), NMI (NMIH), Booz Allen Hamilton (BAH), Skechers USA (SKX), Change Healthcare (CHNG) and Fortinet (FTNT).

R1 RCM's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Hennessy Advisors Inc. (0.24%), Tealwood Asset Management Inc. (0.19%), Calamos Advisors LLC (0.09%) and FNY Investment Advisers LLC (0.00%). Company insiders that own R1 RCM stock include Albert Rene Zimmerli and Charles J Ditkoff. View Institutional Ownership Trends for R1 RCM.

RCM stock was sold by a variety of institutional investors in the last quarter, including Calamos Advisors LLC and Hennessy Advisors Inc.. View Insider Buying and Selling for R1 RCM.

RCM stock was purchased by a variety of institutional investors in the last quarter, including Tealwood Asset Management Inc. and FNY Investment Advisers LLC. View Insider Buying and Selling for R1 RCM.

Shares of RCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RCM stock can currently be purchased for approximately $13.47.

R1 RCM has a market capitalization of $1.52 billion and generates $868.50 million in revenue each year. The healthcare provider earns $-45,300,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. R1 RCM employs 18,600 workers across the globe.View Additional Information About R1 RCM.

The official website for R1 RCM is http://www.r1rcm.com/.

R1 RCM's mailing address is 401 NORTH MICHIGAN AVENUE SUITE 2700, CHICAGO IL, 60611. The healthcare provider can be reached via phone at 312-324-7820 or via email at [email protected]